The choice of an antibacterial drug for urinary infections treatment in children
Keywords:urinary tract infections, children, third generation cephalosporins, cefixime, review
AbstractInfections of the urinary system in childhood take the second place in the frequency of visits for primary medical care. Escherichia coli is the most causative agent of community-acquired forms of infections of the urinary system, which, as a rule, are uncomplicated and are more often diagnosed in girls after three months of age. Klebsiella pneumoniae prevails in nosocomial forms of urinary tract infections, characterized by a complicated course and more often diagnosed in boys up to three months of age. One of the causes of repeated episodes of urinary tract infections is the formation of antibiotic resistance due to the action of β-lactamases of microorganisms on the most commonly used antibacterial drugs of the aminopenicillin group. The literature review substantiates the antibiotic choice for the treatment of urinary infections in children, taking into account the clinical efficacy, safety and sensitivity of the main uropathogens. The results of the randomized clinical trials on the efficacy and safety of the use of the third generation cephalosporin — cefixime in children with urinary tract infections are summarized. Particular attention is paid to maintaining bacterial sensitivity at a level of over 90 % to the action of cefixime in Escherichia coli and Klebsiella pneumoniae, and high compliance with the possibility of a single daily oral administration as an independent therapy on an outpatient basis and the possibility of switching from parenteral use of the third generation cephalosporins to a less invasive, especially in children, oral method.
Abaturov AE, Gerasimenko ON, Agafonova EA, Vysochina IL, Krivusha EL, Nikulina AA. Early diagnosis and antibiotic therapy of urinary tract infections in children. Zdorov`e rebenka. 2012;(37):99-104. (in Russian).
Cefixime. DrugBank Online Catalog. Available from: https://www.drugbank.ca/drugs/DB00671.
Çoban B, Ülkü N, Kaplan H, Topal B, Erdoğan H, Baskın E. Five-year assessment of causative agents and antibiotic resistances in urinary tract infections. Turk Pediatri Ars. 2014 Jun 1;49(2):124-9. doi: 10.5152/tpa.2014.1505.
Edoo Z, Arthur M, Hugonnet JE. Reversible inactivation of a peptidoglycan transpeptidase by a β-lactam antibiotic mediated by β-lactam-ring recyclization in the enzyme active site. Sci Rep. 2017 Aug 22;7(1):9136. doi: 10.1038/s41598-017-09341-8.
El-Jade MR, Parcina M, Schmithausen RM, et al. ESBL Detection: Comparison of a Commercially Available Chromogenic Test for Third Generation Cephalosporine Resistance and Automated Susceptibility Testing in Enterobactericeae. PLoS One. 2016 Aug 5;11(8):e0160203. doi: 10.1371/journal.pone.0160203.
European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2017: Annual report of the European antimicrobial resistance surveillance network (EARS-Net). Available from: https://ecdc.europa.eu/en/publications-data/surveillance-antimicrobial-resistance-europe-2017
Fan NC, Chen HH, Chen CL, et al. Rise of community-onset urinary tract infection caused by extended-spectrum β-lactamase-producing Escherichia coli in children. J Microbiol Immunol Infect. 2014 Oct;47(5):399-405. doi: 10.1016/j.jmii.2013.05.006.
Flokas ME, Detsis M, Alevizakos M, Mylonakis E. Prevalence of ESBL-producing Enterobacteriaceae in paediatric urinary tract infections: A systematic review and meta-analysis. J Infect. 2016 Dec; 73(6):547-557. doi: 10.1016/j.jinf.2016.07.014.
Hameed T, Al Nafeesah A, Chishti S, Al Shaalan M, Al Fakeeh K. Community-acquired urinary tract infections in children: Resistance patterns of uropathogens in a tertiary care center in Saudi Arabia. Int J Pediatr Adolesc Med. 2019 Jun;6(2):51-54. doi: 10.1016/j.ijpam.2019.02.010.
Imran M, Shah MR, Ullah F, et al. Double-tailed acyl glycoside niosomal nanocarrier for enhanced oral bioavailability of Cefixime. Artif Cells Nanomed Biotechnol. 2017 Nov;45(7):1440-1451. doi: 10.1080/21691401.2016.1246451.
Martin D, Fougnot S, Grobost F, et al. Prevalence of extended-spectrum beta-lactamase producing Escherichia coli in community-onset urinary tract infections in France in 2013. J Infect. 2016 Feb;72(2):201-6. doi: 10.1016/j.jinf.2015.11.009.
Moustafa F, Nguyen G, Mathevon T, et al. Evaluation of the efficacy and tolerance of a short 7 day third-generation cephalosporin treatment in the management of acute pyelonephritis in young women in the emergency department. J Antimicrob Chemother. 2016 Jun;71(6):1660-4. doi: 10.1093/jac/dkw021.
Niu H, Yee R, Cui P, et al. Identification and Ranking of Clinical Compounds with Activity against Log-phase Growing Uropathogenic Escherichia coli. Curr Drug Discov Technol. 2018 Aug 7. doi: 10.2174/1570163815666180808115501.
O'Kelly F, Kavanagh S, Manecksha R, Thornhill J, Fennell JP. Characteristics of gram-negative urinary tract infections caused by extended spectrum beta lactamases: pivmecillinam as a treatment option within South Dublin, Ireland. BMC Infect Dis. 2016 Nov 3;16(1):620. doi: 10.1186 / s12879-016-1797-3.
Pistiki A, Tsaganos T, Galani I, Giamarellos-Bourboulis EJ. In Vitro Activity of Oral Cephalosporins (Cefprozil and Cefixime) Against Ciprofloxacin-Resistant Enterobacteriaceae from Community-Acquired Urinary-Tract Infections. Infect Dis Ther. 2015 Dec;4(4):425-32. doi: 10.1007/s40121-015-0089-3.
Robinson JL, Finlay JC, Lang ME, Bortolussi R; Canadian Paediatric Society, Infectious Diseases and Immunization Committee, Community Paediatrics Committee. Urinary tract infections in infants and children: Diagnosis and management. Paediatr Child Health. 2014 Jun;19(6):315-25. doi: 10.1093/pch/19.6.315.
Williams GJ, Wei L, Lee A, Craig JC. Long-term antibiotics for preventing recurrent urinary tract infection in children. Cochrane Database Syst Rev. 2011 Mar 16;(3):CD001534. doi: 10.1002/14651858.CD001534.pub3.
Copyright (c) 2019 A.Ye. Abaturov, A.А. Nikulinа
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our edition uses the copyright terms of Creative Commons for open access journals.
Authors, who are published in this journal, agree with the following terms:
- The authors retain rights for authorship of their article and grant to the edition the right of first publication of the article on a Creative Commons Attribution 4.0 International License, which allows others to freely distribute the published article, with the obligatory reference to the authors of original works and original publication in this journal.
- Directing the article for the publication to the editorial board (publisher), the author agrees with transmitting of rights for the protection and using the article, including parts of the article, which are protected by the copyrights, such as the author’s photo, pictures, charts, tables, etc., including the reproduction in the media and the Internet; for distributing; for the translation of the manuscript in all languages; for export and import of the publications copies of the writers’ article to spread, bringing to the general information.
- The rights mentioned above authors transfer to the edition (publisher) for the unlimited period of validity and on the territory of all countries of the world.
- The authors guarantee that they have exclusive rights for using of the article, which they have sent to the edition (publisher). The edition (the publisher) is not responsible for the violation of given guarantees by the authors to the third parties.
- The authors have the right to conclude separate supplement agreements that relate to non-exclusive distribution of their article in the form in which it had been published in the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
- The policy of the journal permits and encourages the publication of the article in the Internet (in institutional repository or on a personal website) by the authors, because it contributes to productive scientific discussion and a positive effect on efficiency and dynamics of the citation of the article.
- The rights to the article are deemed transferred by the authors to the edition (the publisher) since the moment of the publication of the article in the printed or electronic version of journal.